# Geroscience Computational Engine Architecture

**Status:** Living Systems Blueprint (2026-08-23)  
**Context:** Research infrastructure & open-science tooling for longevity biology.

---

## 1. Executive Summary

Longevity research has historically suffered from three structural bottlenecks:
1. **The Molecule-List Trap:** Treating aging as an unstructured catalog of hundreds of candidate geroprotectors without a formal control-theoretic architecture for damage accumulation.
2. **The L0 Sensor Gap:** Relying on proxy clocks that move without extending functional healthspan, and using uncoupled clinical endpoints (e.g., MoCA vs. CogState, single-timepoint frailty vs. continuous intrinsic capacity).
3. **The Publication Bias / Negatives Chasm:** Over 50% of longevity-relevant trials marked `COMPLETED` on public registries (CT.gov, UMIN, ChiCTR, ISRCTN) never publish comprehensive results tables or effect sizes, poisoning meta-analyses and misdirecting capital.

This repository provides an open computational substrate that unifies:
- **Two-Pathway Damage Boundedness Simulator** (`algorithms/damage_control.py`)
- **Stochastic Saturating Removal (SR) Multi-Species & Morbidity Compression Engine** (`algorithms/saturating_removal.py`)
- **Intervention Portfolio & Hallmark Synergy Optimizer** (`algorithms/portfolio_optimizer.py`)
- **Clinical Trial Transparency & Evidence Maturity Auditor** (`algorithms/trial_transparency.py`)
- **Hallmarks-of-Aging Driver Topology Graph** (`algorithms/hallmarks_graph.py`)

---

## 2. Mathematical Foundation: Control Theory & Damage Dynamics

### 2.1 The Two-Pathway Boundedness Model
Organismal damage burden $D(t) = A(t) + B(t)$:
- **$A(t)$ (Regulatable Lesions):** Proteostatic load, metabolic dysfunction, reversible SASP, NAD depletion. Endogenous clearance capacity $R_A$ can be stimulated through systemic setpoints (L1/L2/L3).
- **$B(t)$ (Information-Limited Lesions):** Oncogenic clonal expansion (CHIP), fixed somatic mosaic mutations, permanent cell loss, advanced crosslinks (glucosepane), irreversible mitochondrial heteroplasmy. Requires engineered detection and physical correction/replacement ($R_B$).

**Theorem (Barkman 2026):** $D(t)$ stays bounded for all $t$ if and only if $R_A > \text{prod}(A)$ **and** engineered $R_B > \text{prod}(B)$. Any open-loop single-pathway strategy fails asymptotically.

### 2.2 Saturating Removal (SR) Dynamics (Uri Alon / Karin Lab 2026 Formulation)
$$\frac{dD}{dt} = \eta t - \frac{\beta D}{\kappa + D} + \epsilon \xi(t)$$
- **Ballistic Regime ($\eta t \gg \beta$):** Damage production rapidly saturates clearance capacity. Characterizes short-lived species (yeast, C. elegans, Drosophila, mice) exhibiting Weibull-like mortality trajectories.
- **Quasi-Steady-State Regime ($\eta t \approx \frac{\beta D}{\kappa + D}$):** Damage tracks a slowly moving setpoint of production balanced by clearance until extreme old age. Characterizes long-lived mammals (humans, dogs, cats) exhibiting Gompertzian mortality kinetics.
- **Morbidity Compression Law:** Slowing damage production $\eta$ alone (e.g., caloric restriction) extends both lifespan and absolute sickspan. True morbidity compression ($T_{\text{sick}} / T_{\text{life}} \downarrow$) mathematically requires a tripartite intervention: $\eta \downarrow$ (production reduction) + $\beta \uparrow$ (clearance acceleration) + $X_c \uparrow$ (damage tolerance elevation).

---

## 3. The 6-Layer Longevity Control Stack

```
┌─────────────────────────────────────────────────────────────┐
│ L6  MODULAR REPLACEMENT   organs, stem cell niches, ECM    │
│ L5  INFORMATION CONTROL   clone purging, base editors, AGE │  ← Pathway B
│ L4  EPIGENETIC RESET      pulsed OSK(M), partial reprogram  │
│ L3  CELLULAR CLEARANCE    senolytics, senomorphics, immune │
│ L2  REPAIR ECONOMY        NAD+, PARP/sirtuin, BER/NER/HR   │  ← Pathway A
│ L1  DAMAGE REDUCTION      metabolic setpoint, inflammaging │
└─────────────────────────────────────────────────────────────┘
          ↑ L0 Continuous Sensing & Multi-Omic Feedback
```

---

## 4. Operational Geroscience Tool Suite

### 4.1 Comparative Geroscience Simulator
```powershell
python -m algorithms.saturating_removal --compare --species human
python -m algorithms.saturating_removal --all-species
```
Simulates cross-species lifespans, healthspans, sickspans, and calculates the exact morbidity compression delta under single vs. multi-target intervention paradigms.

### 4.2 Portfolio & Cocktail Optimizer
```powershell
python -m algorithms.portfolio_optimizer --eval vital_h_triad laromestrocel_msc sif001_gal3_mab progerinin
python -m algorithms.portfolio_optimizer --optimize --max-size 4
python -m algorithms.portfolio_optimizer --drivers
```
Computes hallmark coverage across primary, antagonistic, and integrative tiers; quantifies pairwise mechanism overlap (redundancy index); and solves the minimal set-cover problem for non-redundant geroprotective cocktails.

### 4.3 Trial Transparency & Negatives Auditor
```powershell
python -m algorithms.trial_transparency --audit
python -m algorithms.trial_transparency --list-trials
```
Audits the elapsed evidence delay between trial completion dates and public data disclosure across global registries (ClinicalTrials.gov, UMIN, ChiCTR, ISRCTN), eliminating publication bias in translational longevity roadmaps.

---

## 5. Industry Value Proposition

| Stakeholder | Direct Benefit |
|-------------|----------------|
| **Longevity Biotech (Pharma / Startups)** | Evaluates candidate combinatorial pipelines for target orthogonality, multi-hallmark span, and cancer risk from premature reprogramming before committing capital to multi-year preclinical or clinical studies. |
| **Geroscience Trial Designers (Academic / CRO)** | Formalizes L0 endpoint selection (harmonizing PROSPR-IC vs. XPRIZE triads) and establishes strict transparency audits for competitor pipelines. |
| **Biomarker & Diagnostics Developers** | Connects molecular aging clocks (epigenetic, transcriptomic, proteomic) directly to underlying damage-accumulation differential equations rather than correlational age-matching alone. |
| **Venture Capital & Grant Funders** | Delivers an objective Evidence Tiering matrix (Tier 1 Preclinical $\to$ Tier 4 Phase III Hard Endpoint RCT) and flags undisclosed completed trials to prevent duplicate funding. |
